New drug cocktail aims to beat deadly fungus in blood cancer patients
NCT ID NCT07185503
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a combination of two antifungal drugs—liposomal amphotericin B plus either posaconazole or isavuconazole—in 60 adults with blood cancers who also have a serious fungal infection called mucormycosis. The goal is to see if the combo can clear the infection better and with fewer side effects than standard treatments. Participants will be closely monitored for symptom improvement, side effects, and survival over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal amphotericin B combined with posaconazole or isavuconazole
What this could lead to
If this works, it could offer a more effective and safer treatment option for a deadly fungal infection in people with blood cancers.
What could go wrong
This is a small, early-phase study with only 60 participants and no comparison group. The combination may still cause serious side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGTianjin, China
Contact Email: •••••@•••••
-
Second Hospital of Tianjin Medical University
NOT_YET_RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shengjing Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITINGHarbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Hospital of Dalian Medical University
NOT_YET_RECRUITINGDalian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin First Central Hospital
NOT_YET_RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Haihe Hospital
NOT_YET_RECRUITINGTianjin, China
Contact Phone: •••-•••-••••
-
Tianjin Union Medical Center of Nankai University
NOT_YET_RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••